Treatment on TAPUR Trial: Pembrolizumab

• Prospective, non-randomized clinical trial (NCT02693535)
• Assesses safety and efficacy of targeted therapies
• Therapy is selected based on genomic testing results
• Allows off-label access based on biology, not tumor site

• PD-1
• An inhibitory immune checkpoint receptor expressed on T cells, PD-1 induces signaling that inhibits T-cell proliferation, cytokine release and cell death
• PD-L1
• A PD-1 ligand that serves as an immunosuppressive signal
• Expressed in many malignancies, including breast cancer
• Pembrolizumab is a monoclonal antibody against PD-1; as a result, the immune system is not hindered from targeting cancer cells
• There is evidence of efficacy in patients with metastatic, triple-negative breast cancer

• Patient received first cycles of pembrolizumab
• Significant fatigue, intermittent abdominal pain
• Initial follow-up scans stable
• Second dose held twice due to LFT abnormalities
• Ultimately removed from protocol because of LFT abnormalities
• Transitioned to supportive care only

References:

1. https://www.tapur.org/sites/tapur.org/files/03.2018_General_TAPUR_Overview.pdf
2. http://ascopubs.org/doi/10.1200/JCO.2015.64.8931